Encompass Health Corporation Stock Price and Value Analysis

Encompass Health Corporation (NYSE:EHC) in our automated value investing analysis, with the cash flow history and price comparison below.

Key Facts

Advertisement helps keep Trendshare free for most readers.

Hold-time calculator

Estimate how long you need to hold Encompass Health Corporation to reach your target.

Target type

EHC Free Cash Flow Trend

Free Cash Flow trendline for EHC
Free Cash Flow trendline for Encompass Health Corporation
CSV

Based on historical returns, we believe that Encompass Health Corporation can grow its free cash at a rate of about 7%. That's positive!

AdvantagesDisadvantages
  • This company has stable growth.
  • This company is making money at a decent rate.
  • This stock looks overpriced.
  • This company is less known than others.
  • This company has a low dividend yield.

Inside the EHC Numbers

EHC Price
(Encompass Health Corporation stock price per share)
$132.28
[?] EHC Fair Price
(based on intrinsic value)
$24.85
[?] EHC Safety Price (based on a variable margin of safety) $14.91
Try your own return

The fair price above uses a 10.1% discount rate, the long-run US stock return (10.1% geometric, 1926 to 2025, from Bessembinder's working paper, updated 2026-11-09), and 2.5% terminal growth. A higher rate suits a higher return target and gives a lower value.

Value per share:

[?] PE Ratio versus Sector 4% higher than other Healthcare stocks
[?] PE Ratio versus Industry 0% lower than other Medical Care Facilities stocks
[?] Free Cash Flow Jitter 22%
[?] Dividend Yield 0.58% (tax impact)
Shares Shorted 3,613,983

Insider Activity Summary

No open-market insider buys or sells are recorded for the last 12 months.

This stock has short interest! This means that people have shorted it.

Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.

As of the latest analysis, there are 3,613,983 shares shorted. With 97,147,283 shares available for purchase and an average trading volume over the past 10 trading days of 927,580, it would take at least 3.9 days for all of the short holders to cover their shorts.

Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth

Free Cash Flow by Fiscal Year

How to read this: free cash flow in plain terms, free cash flow jitter.

Each year names the SEC filer that reported it, so a change of filer shows up here.

Fiscal yearSEC filer (CIK)Free cash flow (USD millions)
2008 785161 172
2009 785161 347
2010 785161 270
2011 785161 272
2012 785161 327
2013 785161 358
2014 785161 311
2015 785161 355
2016 785161 478
2017 785161 479
2018 785161 571
2019 785161 404
2020 785161 420
2021 785161 358
2022 785161 276
2023 785161 355
2024 785161 453
2025 785161 557

Download the yearly data as CSV.

Cash Conversion

How to read this: what free cash flow is, why earnings matter.

Over the 18 fiscal years from 2008 to 2025 with positive net income, operating cash flow totaled $10,987 million against net income of $5,880 million, or 1.87 times.

In 2025, operating cash flow was 2.08 times net income, compared with 0.77 times for the earliest three years (2008 to 2010).

In 2025, capital expenditures were $736 million, 62.6% of operating cash flow of $1,176 million, which leaves an estimated $439 million after capex. Across the 18 years with reported capex, it averaged 49.4% of operating cash flow. This uses that year's own capital expenditures, not the five-year average behind the free cash flow table, so the two can differ.

Fiscal yearNet income (USD millions)Operating cash flow (USD millions)Capital expenditures (USD millions)Operating cash flow / net income
2008 252 227 55.7 0.90
2009 94.8 406 63.3 4.28
2010 899 331 62.8 0.37
2011 209 343 100 1.64
2012 185 412 141 2.22
2013 324 470 195 1.45
2014 222 445 171 2.00
2015 183 502 128 2.74
2016 248 640 178 2.59
2017 271 658 226 2.43
2018 292 762 255 2.61
2019 359 635 372 1.77
2020 284 705 393 2.48
2021 412 716 546 1.74
2022 271 706 584 2.60
2023 352 851 583 2.42
2024 456 1,003 643 2.20
2025 566 1,176 736 2.08

Where the Cash Went

How to read this: why companies buy back shares, dividend yield explained.

Over the 10 fiscal years from 2016 to 2025 with dividend or share repurchase facts, estimated free cash flow totaled $4,350 million. That estimate uses the average of up to five years of capital expenditures, not each year's own, so it is not a reported figure.

In the 10 of those years with dividend payment facts, dividends paid totaled $902 million, 20.7% of the estimated free cash flow of those years. Estimated free cash flow was at least the dividends paid in 10 of those 10 years.

In 5 of the 10 years, cash spent repurchasing shares was at least 5% of that year's estimated free cash flow, and in those years it totaled $339 million. Smaller amounts are left out of this sentence because they can be shares withheld to pay employees' taxes on stock awards.

In 2025, dividends and cash spent repurchasing shares together were $229 million, 41.1% of estimated free cash flow of $557 million.

Fiscal yearEstimated free cash flow (USD millions)Dividends paid (USD millions)Cash spent repurchasing shares (USD millions)Total returned (USD millions)Total as a percent of estimated free cash flow
2016 478 83.8 65.6 149 31.3%
2017 479 91.5 38.1 130 27.1%
2018 571 101 n/a 101 17.7%
2019 404 109 45.9 155 38.3%
2020 420 112 6.1 118 28.1%
2021 358 112 n/a 112 31.4%
2022 276 99 n/a 99 35.9%
2023 355 60.4 n/a 60.4 17.0%
2024 453 62.8 31.1 93.9 20.7%
2025 557 71.1 158 229 41.1%

Free cash flow here is an estimate: operating cash flow less the average of up to five years of capital expenditures. Cash spent repurchasing shares can include shares withheld to pay employees' taxes on stock awards. The entry n/a means the filings gave no usable figure, not that the amount was zero. Source: the company's annual reports to the SEC.

Revenue and Cash Margin

How to read this: earnings and margins.

Revenue was $3,643 million in 2016 and $5,935 million in 2025, a compound annual growth rate of 5.6% over 9 years.

Revenue rose 10.5% from 2024 to 2025.

Our estimated free cash flow was $557 million in 2025, 9.4% of revenue. In 2016 the estimated margin was 13.1%. This estimate charges each year with the average of up to five years of capital expenditures, so it is not the free cash flow the company reported.

Fiscal yearRevenue (USD millions)Estimated free cash flow (USD millions)Estimated free cash flow / revenue
2016 3,643 478 13.1%
2017 3,914 479 12.2%
2018 4,277 571 13.3%
2019 4,605 404 8.8%
2020 3,566 420 11.8%
2021 4,015 358 8.9%
2022 4,349 276 6.3%
2023 4,801 355 7.4%
2024 5,373 453 8.4%
2025 5,935 557 9.4%

Balance Sheet

How to read this: how debt and assets are compared, the current ratio.

In 2025, cash and equivalents were $72.2 million against total liabilities of $3,814 million, or 1.9% of total liabilities. Total liabilities include everything the company owes, not only borrowed money.

Total liabilities were 53.8% of total assets in 2025, compared with 153.4% in 2009, a decrease of 99.6 percentage points.

Stockholders equity was $3,218 million in 2025, up from negative equity of -$821 million in 2009.

Based on our estimated free cash flow, cash flow return on invested capital (CROIC) was 9.0% in 2025. Invested capital here is total assets less cash and current liabilities.

Fiscal yearTotal assets (USD millions)Cash and equivalents (USD millions)Total liabilities (USD millions)Stockholders equity (USD millions)
2009 1,682 80.7 2,579 -821
2010 2,372 48.3 2,375 -2.2
2011 2,271 30.1 2,070 202
2012 2,424 133 2,014 404
2013 2,534 64.5 2,052 469
2014 3,388 66.7 2,684 620
2015 4,606 61.6 3,720 779
2016 4,682 40.5 3,633 929
2017 4,865 54.4 3,248 1,395
2018 5,175 69.2 3,356 1,557
2019 6,081 60 4,148 1,693
2020 6,446 186 4,444 1,970
2021 6,865 49.4 4,466 2,357
2022 5,637 21.8 3,775 1,826
2023 6,102 69.1 3,805 2,255
2024 6,535 85.4 3,686 2,793
2025 7,090 72.2 3,814 3,218

Price Versus Our Estimated Value

Free cash flow was positive in all 18 fiscal years we have for Encompass Health Corporation under its current SEC filer.

Encompass Health Corporation is priced at $132.28, above our fair value estimate of $24.85 and its safe value of $14.91.

Encompass Health Corporation's average free cash flow rose sharply, from $263 million in its earliest three years to $455 million in its latest three.

Free cash flow is fairly steady from year to year, with a variability measure of 22%.

Encompass Health Corporation yields 0.58% in dividends.

Our value investing guide explains how to test these numbers against the filings themselves.

Compared With Its Sector and Industry

How to read this: the price to earnings ratio.

Its trailing P/E ratio is 4% above the average for stocks in the Healthcare sector.

Its trailing P/E ratio is in line with the average for stocks in the Medical Care Facilities industry.

A P/E ratio depends on trailing earnings, which one-time items can distort, so a lower P/E is not by itself evidence of value.

Closest Industry Peers

These are companies in the Medical Care Facilities industry, the ones closest in market capitalization to Encompass Health Corporation, limited to companies whose pages we publish. The figures come from our latest data for each company.

CompanyMarket cap (USD millions)P/EDividend yieldCash yieldPrice versus our estimate
Encompass Health Corporation (EHC) 12,980 21.2 0.6% - 432% above
Universal Health Services (UHS) 10,088 7.3 0.4% 14.1% 72% below
DaVita (DVA) 9,834 11.8 - 15.2% 59% below
Tenet Healthcare Corporation (THC) 20,979 7.7 - 7.5% 21% below
Surgery Partners (SGRY) 3,493 - - - 104% above
Progyny (PGNY) 2,611 32.5 - - 406% above
Healthcare Services Group (HCSG) 1,670 16.7 - 4.0% 17% below

Industry labels are approximate, and companies in one industry can run quite different businesses, so a peer may not be a close match.

Ratios on different fiscal calendars are not strictly comparable, and a trailing P/E can be distorted by one-time items.

SEC Filer History

Every fiscal year on this page is reported by one SEC filer, CIK 785161.

Each figure on this page comes from that filer.

Risks to This Analysis

How to read this: understanding investment risk.

  • These figures are automated calculations from SEC filings and the recent price. They may contain errors, and they do not reflect lawsuits, management changes, or other events the filings do not show.

How This Page Is Made

Latest annual report used
Fiscal year 2025
Price and market data last refreshed
2026-11-19
Model assumptions last reviewed
2026-11-09

Company figures come from the annual reports (Form 10-K) that each company files with the SEC, read from the SEC EDGAR company facts data. The share price and other market data come from a market data provider.

Free cash flow here is operating cash flow minus capital spending. To keep one unusual year from swinging the result, each year is charged with the average of up to five years of capital spending, so the figure is an estimate and not the free cash flow a company reports.

The fair price is the present value of ten years of projected free cash flow plus a terminal value, discounted at 10.1 percent a year, the long-run return of US stocks, with 2.5 percent growth after year ten. The figures on this page are estimates, not advice.

This analysis covers US companies that file 10-K annual reports. Free cash flow describes banks, real estate investment trusts and funds poorly, so treat their figures with extra caution. In the cash returned and balance sheet tables, a value of zero is treated as a gap in the data, not as a real zero.

Read the filings yourself: EHC annual reports (10-K) on SEC EDGAR. To try your own growth rate, use the intrinsic value calculator on this page. Our editorial standards explain how Trendshare handles its sources and corrections.

Advertisement supports free stock analysis content.

Questions to Answer Before You Invest in EHC

Does Encompass Health Corporation have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.

Worked example: EHC

This example shows how we apply the Trendshare checklist to EHC: earnings power, cash generation, valuation, and margin of safety.

We check: business quality, free cash flow, P/E, and margin of safety.

  1. Step 1 — Snapshot

    • Price: 132.28
    • Market cap: $13B
    • EPS: 6.25
  2. Step 2 — Valuation checks

    • P/E: 21.165
    • FCF yield: —
    • Date checked: Nov 19, 2026
  3. Step 3 — Margin of safety

    • Compare price to fair value and safety price.
    • Look for durable cash generation and reasonable leverage.
    • Decide if it passes your personal checklist.